Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Amazon’s latest ad format offers a glimpse of advertising’s agentic future
Amazon’s Alexa+ agentic ads bring advertising into AI shopping conversations, raising questions about paid versus organic visibility.
Cannes Briefing: Cannes is selling AI transformation. Off stage the talk is about the bill
The quiet part of the AI conversation at Cannes: what it actually costs
Connect, don’t absorb: Dept’s AI bet on orchestration over operating systems
Dept’s AI assistant already touches a fifth of its revenue. It wants 80% by next year.